Vivek Subbiah
The University of Texas MD Anderson Cancer Center · 1,502 works · 32,884 citations · h-index 80
Top works
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
- Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer
- Efficacy of Selpercatinib in RET -Altered Thyroid Cancers
- Efficacy of Selpercatinib in RET Fusion–Positive Non–Small-Cell Lung Cancer
- Vemurafenib for BRAF V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis
- Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial
- The next generation of evidence-based medicine
- Selective RET kinase inhibition for patients with RET-altered cancers
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study
- Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
- Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study
- Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
- Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial
- Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
- Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation
- BRAF Inhibition in BRAF V600 -Mutant Gliomas: Results From the VE-BASKET Study
- Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study
- RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
- 695P A phase I/Ib study evaluating the safety and tolerability of NIZ985 alone and in combination with spartalizumab (anti–PD-1) in patients (pts) with solid tumors or lymphoma